Press Releases

Rep. Frankel Statement on Federal Allocation of Monoclonal Antibodies

f t # e
Washington, January 27, 2022 | comments

West Palm Beach, FL – Today, Congresswoman Lois Frankel (FL-21) released the following statement after a bipartisan briefing from the Department of Health and Human Services. Members of Congress heard directly from leaders of the federal COVID-19 response team that federal agencies are continuing to follow the science and data in making decisions for the health and well-being of all Americans. 

“Public health experts from the FDA, CDC, and other federal agencies have been working tirelessly to ensure every American who gets COVID-19 has access to the treatment they need,” said Rep. Frankel. “The Biden Administration is following the science of which monoclonal antibody treatments are effective and updating guidance and shipments accordingly. Misleading statements by some elected officials are for the purpose of scoring political points not saving lives.”

On Monday, following data from manufacturers themselves as well as independent studies, the FDA revoked its Emergency Use Authorizations for two COVID-19 monoclonal antibody treatments that are not effective at neutralizing the Omicron variant, which currently accounts for over 95 percent of cases nationwide. The Biden Administration is working closely with manufacturers of treatments that remain effective to maximize production and distribute treatments nationwide based on factors including numbers of cases and hospitalizations. Florida has consistently received one of the highest allocations of any state.

More information about the authorization status of various COVID-19 treatments can be found here.

More information about COVID-19 prevention and treatment can be found here.

Updates about Palm Beach County’s COVID-19 response can be found here.


f t # e